Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699515 | 1.00 | MMP1 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL13912226 | 1.00 | MMP1 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL19736325 | 0.82 | CNR1 (0.39) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL27118233 | 0.82 | USP2 (0.52) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL2309969 | 0.82 | MMP1 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL8224748 | 0.82 | MMP1 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL9966033 | 0.82 | MMP1 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL22387540 | 0.81 | ACACB (0.37) | MMP1MMP2MMP3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13374576 | 0.80 | MMP1 (0.48) | MMP1MMP2MMP3SMN1; SMN2PKM | |
| SCHEMBL19062100 | 0.80 | DPP4 (0.50) | MMP1MMP2MMP3SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023192961-A2 | LIGAND-PAYLOAD CONJUGATES | PYXIS ONCOLOGY, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210308269-A1 | Small Molecule Drug Conjugates | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-08 | — | — | US | disclosed |
| US-20150005278-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| WO-2013187971-A2 | MACROCYCLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | WO | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-4143047-A | 2-SULFINYL AND 2-SULFONYL OXAZOLES | LILLY INDUSTRIES LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MMP1 3720/4885MMP2 2960/4885MMP3 4140/4885 |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | MMP1 4767/4885MMP2 4088/4885MMP3 4127/4885 |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MMP1 223/4885MMP2 968/4885MMP3 1458/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | MMP1 393/4885MMP2 613/4885MMP3 696/4885 |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | MMP1 4795/4885MMP2 4384/4885MMP3 4556/4885 |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | MMP1 4423/4885MMP2 3801/4885MMP3 2740/4885 |
| US-20150005278-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, SIK2, PDXK | MMP1 4724/4885MMP2 4642/4885MMP3 4020/4885 |
| US-20210308269-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | MMP1 2221/4885MMP2 332/4885MMP3 1177/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | MMP1 3658/4885MMP2 2811/4885MMP3 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.